Cephalon moving more rapidly on oncology candidate Treanda.
Glaxo’s cervical cancer vaccine Cervarix looking good.
Byetta, a diabetes drug from Amylin and Lilly, shows solid results after 3 years of usage.
More good press for Actos, Takeda’s competitor to Avandia.
Cholesterol agents acting against diabetic nerve pain?
Two-pronged approach to treating diabetes – the DPP-4 inhibitor plus metformin combination.
Bayer pursuing the hope of selling a low-dose statin OTC.
Pfizer hits snags with experimental cancer and HIV treatments.
Pfizer’s Lyrica gets clearance for Fibromyalgia indication. Question – where did the 1 in 50 statistic come from??
Novartis’ growing high blood pressure franchise. Now featuring ExForge.
From the scandal sheet – BMS, Schering, AZ lose Massachusetts suit over drug pricing. Here is a more detailed analysis of the AWP issue. And, Pfizer’s growing headaches with possible internal violations on HIV (Viracept) marketing.
How to schmooze any doc, from a former Zyprexa rep. Not really news to anyone involved in sales training, but it’s just one more check mark on the “looks bad to the public” tally sheet.
Some thoughts on patient adherence/compliance, from the ever-thoughtful Jane Chin.